U.S. FDA approves Mirati's lung cancer drug

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

The U.S. Food and Drug Administration approved Mirati Therapeutics Inc's lung cancer drug adagrasib, the company said on Monday, sending its shares up more than 8% in extended trading.

Mirati's drug has been approved for treating adult patients with advanced lung cancer as determined by an FDA-approved test, who have received at least one prior systemic therapy.